Security key
29842P105
EUPRAXIA PHARMACEUTICALS INC. - Common Shares, no par value (EPRX)
CUSIP: 29842P105
Q1 2026 13F Holders as of 31 Mar 2026
- Security type / class
- Equity / Common Shares, no par value
- Total 13F shares
- 21,984,367
- Total 13F value
- $156,495,266
- Share change
- +8,148,073
- SEC-reported price per share
- $7.24
- Number of holders
- 53
- Value change
- +$58,795,150
- Number of buys
- 40
- Number of sells
- 8
- Shares outstanding
- 52,146,078
Holder snapshot
6 signals
Security identity
1 source field
Report period
Q1 2026
Institutions
53
Top holders
10
EPRX full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q4 2025
EUPRAXIA PHARMACEUTICALS INC. SEC filings
EUPRAXIA PHARMACEUTICALS INC. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 29842P105
Recent filing periods:
Ownership snapshot
Top reported holders of EPRX - EUPRAXIA PHARMACEUTICALS INC. - Common Shares, no par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Joseph S. Freedman
Disclosed value leader
Joseph S. Freedman
Comparable rows
15/15
Latest evidence
31 Mar 2026
13D/G
13F
Lead comparable stake: 9%
13D/G row: Joseph S. Freedman
Showing 1-6 of 15 holder rows.
Quick read
Joseph S. Freedman leads the comparable SEC ownership view at 9%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Comparable ownership
Top 5
Joseph S. Freedman
9%
Beutel, Goodman & Co Ltd.
8%
MANCHESTER MANAGEMENT CO LLC
7.7%
Robert Disbrow
7%
BALYASNY ASSET MANAGEMENT L.P.
2.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Joseph S. Freedman |
13D/G
|
9%
|
$47,037,881
5,843,215 shares
|
+$2,495,500 | 13 Mar 2026 |
| Beutel, Goodman & Co Ltd. |
13F
13D/G
Company
|
8%
from 13D/G
|
$27,926,000
3,709,373 shares
|
— | 31 Dec 2025 |
| MANCHESTER MANAGEMENT CO LLC |
13D/G
Morgan C. Frank
|
7.7%
|
$28,829,481
4,015,248 shares
|
-$6,384,994 | 31 Mar 2026 |
| Robert Disbrow |
13D/G
|
7%
|
$21,052,085
3,568,150 shares
|
$0 | 30 Sep 2025 |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
Company
|
2.6%
|
$10,192,500
1,350,000 shares
|
— | 31 Dec 2025 |
| Vivo Capital, LLC |
13F
Company
|
2.6%
|
$10,192,500
1,350,000 shares
|
— | 31 Dec 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
53
Shares
21,984,367
Rows available
53
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
35
Q1 2026 holders
53
Holder diff
18
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 value | Q1 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend